Postmarket surveillance data revealed that enfortumab vedotin (EV) skin toxicity is associated with high hospitalization and ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

The deadline to make a claim in the $177 million settlement is coming soon. Here's what customers should know.

LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) Disease remission reported as DORIS response seen in 2 out of 3 ...

Day One Biopharmaceuticals, Inc. is rated a Strong Buy with robust product growth, pipeline expansion & strategic acquisition ...

Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver ...

Allo-Evasion™ 5.0-engineered iPSC beta islets are designed to overcome immune rejection and provide durable glucose control without chronic immunosuppressionCompelling preclinical data demonstrate ...

Sjögren’s Disease (SD) In October 2025, Vor Bio’s and its collaborator, RemeGen Co., Ltd, reported positive top-line Phase 3 results from the study of telitacicept in Sjögren’s disease in China. The ...

From e-health records to a biotech hub in Tartu, Estonia is harnessing data, digital infrastructure, and investment to drive ...

It's powerful, it's clean, and it's got battery life for days, but the OnePlus 15 isn't the jack of all trades that its ...

Denisse Aranda '10 is a principal space systems contamination control engineer at Blue Origin. She’s the lead contamination ...

Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society ...